![]() |
|
|
Vol. 292, Issue 1, 261-264, January 2000
Department of Pediatrics, Division of Cardiology, Tulane University
School of Medicine, New Orleans, Louisiana
Recently, there has been considerable attention focused on drugs that
prolong the QT interval of the electrocardiogram, with the
H1-receptor antagonist class of drugs figuring prominently. Albeit rare, incidences of QT prolongation and ventricular arrhythmias, in particular torsade de pointes, have been reported with the antihistamines astemizole and terfenadine and more recently with loratadine. The most likely mechanism for these drug-related
arrhythmias is blockage of one or more ion channels involved in cardiac
repolarization. Several studies have demonstrated block of multiple
cardiac K+ channels by terfenadine, including
Ito, Isus,
IK1, and IKr or human ether-a-go-go-related gene (HERG). In contrast to terfenadine, previous studies have shown the antihistamine loratadine to be virtually free of cardiac ion channel-blocking effects. This disparity in the lack of any significant cardiac ion channel-blocking effect and
the existence of numerous adverse cardiac event reports for loratadine
prompted the comparison of the human cardiac K+
channel-blocking profile for loratadine and terfenadine under physiological conditions [37°C, holding potential
(Vhold) =
75 mV] with the
whole-cell patch-clamp method. Isolated human atrial myocytes were used
to examine drug effects on Ito,
Isus, and IK1, whereas HERG was studied in stably transfected HEK cells. In contrast to previous studies in nonhuman systems and/or under nonphysiological conditions, terfenadine (1 µM) had no effect on
Ito, Isus, or IK1 at pacing rates up to 3 Hz. Similar
results were found for 1 µM loratadine. However, both drugs potently
blocked HERG current amplitude, with a mean IC50 of 173 nM
for loratadine and 204 nM for terfenadine (pacing rate, 0.1 Hz).
Neither drug exhibited any significant use-dependent blockage of HERG
(pacing rates = 0.1-3 Hz). These results point to a similarity in
the human cardiac K+ channel-blocking effects of loratadine
and terfenadine and provide a possible mechanism for the arrhythmias
associated with the use of either drug.
This article has been cited by other articles:
![]() |
A. Finkel, A. Wittel, N. Yang, S. Handran, J. Hughes, and J. Costantin Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents J Biomol Screen, August 1, 2006; 11(5): 488 - 496. [Abstract] [PDF] |
||||
![]() |
A. N. Katchman, J. Koerner, T. Tosaka, R. L. Woosley, and S. N. Ebert Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1098 - 1106. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ekins, W. J. Crumb, R. D. Sarazan, J. H. Wikel, and S. A. Wrighton Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 427 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cavero and W. Crumb Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K53 - K63. [Abstract] [PDF] |
||||